公开(公告)号：US12077584B2

公开(公告)日：2024-09-03

申请号：US17670398

申请日：2022-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Natalie Bezman ,  Alan J. Korman ,  Shrikant Deshpande ,  Amy D. Jhatakia ,  Richard Y. Huang ,  Guodong Chen ,  Ginger C. Rakestraw ,  Karla Ann Henning ,  Vangipuram S. Rangan ,  Christine Bee ,  Xiang Shao

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K1/22 ,  C12N5/071 ,  C12N15/85 ,  C12P21/00 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K47/6849 ,  A61P35/00 ,  C07K1/22 ,  C12N5/0682 ,  C12N15/85 ,  C12P21/005 ,  G01N33/68 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02 ,  C12N2800/107

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

公开(公告)号：US20240287452A1

公开(公告)日：2024-08-29

申请号：US18441393

申请日：2024-02-14

Applicant: Seattle Children's Hospital (dba Seattle Children's Research Institute)

Inventor： David J. Rawlings ,  Richard James ,  Shaun W. Jackson ,  Iram Khan ,  King Hung ,  Andrew M. Scharenberg

IPC: C12N5/078 ,  A61K35/17 ,  A61K48/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/0781 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N5/0634 ,  A61K48/0058 ,  C07K14/00 ,  C07K16/00 ,  C12N5/0635 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K35/17 ,  C07K2317/14 ,  C07K2317/21 ,  C12N15/113 ,  C12N2310/20 ,  C12N2501/056 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2315 ,  C12N2501/24 ,  C12N2501/52 ,  C12N2506/11 ,  C12N2510/00 ,  C12N2510/02 ,  C12N2750/14143 ,  C12N2800/80

Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.

公开(公告)号：US20240287451A1

公开(公告)日：2024-08-29

申请号：US18656253

申请日：2024-05-06

Applicant: Genzyme Corporation

Inventor： Agata Villiger-Oberbek ,  Jianguo Yang ,  Yang Yang ,  Gabrielle Lorenzo

IPC: C12N5/071 ,  C12M1/00 ,  C12M1/32 ,  C12M3/04 ,  C12P21/00

CPC classification number: C12N5/0602 ,  C12M23/12 ,  C12M27/10 ,  C12M29/10 ,  C12P21/00 ,  C12N2510/02 ,  C12N2527/00

Abstract: Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods. Also provided are multi-well cell culture plates, e.g., for use in perfusion culturing methods.

公开(公告)号：US11952605B2

公开(公告)日：2024-04-09

申请号：US18172670

申请日：2023-02-22

Applicant: AMGEN INC.

Inventor： Jian Wu ,  Sean Davern ,  Simina Crina Petrovan ,  Michael Charles Brandenstein ,  Katherine Rose Lindahl ,  Shawn Erik Lillie

IPC: C12P21/00 ,  C07K16/00 ,  C12N1/38 ,  C12N5/00

CPC classification number: C12P21/005 ,  C07K16/00 ,  C12N1/38 ,  C12N5/0037 ,  C07K2317/14 ,  C07K2317/41 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2510/02

Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.

公开(公告)号：US11939387B2

公开(公告)日：2024-03-26

申请号：US18047039

申请日：2022-10-17

Applicant: SHANGHAI MABGEEK BIOTECH. CO., LTD.

Inventor： Chenghai Zhang ,  Jinlin Guo ,  Yujing Yuan

IPC: C07K16/28 ,  A61K39/395 ,  A61P11/06 ,  C12N5/16 ,  A61K39/00 ,  C07K14/705

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61P11/06 ,  C07K16/2896 ,  C12N5/16 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2510/02

Abstract: The present invention discloses an antibody capable of binding to human interleukin 4 receptor alpha (hIL-4R alpha) and a preparation method and application thereof. The anti-hIL-4R alpha antibody can specifically bind to hIL-4R alpha, has good effects for inhibiting IL-4 and IL-13-induced cell line proliferation and the like, and can be applied to treatment of IL-4R alpha related diseases, such as immune-mediated inflammatory diseases.

公开(公告)号：US11932873B2

公开(公告)日：2024-03-19

申请号：US17101780

申请日：2020-11-23

Applicant: Innovative Cellular Therapeutics Holdings, Ltd.

Inventor： Zhao Wu

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001112 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/30 ,  C12N5/0638 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/02

Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

公开(公告)号：US11912776B2

公开(公告)日：2024-02-27

申请号：US17695769

申请日：2022-03-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K14/705 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  C12N5/10 ,  C07K14/725 ,  A61K31/7076 ,  C12N15/63 ,  A61K35/17 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K31/7076 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/46 ,  A61K39/4631 ,  A61K39/464417 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/63 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K16/2863 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2510/02

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US20240043879A1

公开(公告)日：2024-02-08

申请号：US18467658

申请日：2023-09-14

Applicant: Cytiva Sweden AB

Inventor： Daniel Ivansson ,  Andreas Castan

IPC: C12N15/90 ,  C12P21/00 ,  C07K16/00

CPC classification number: C12N15/907 ,  C12P21/00 ,  C07K16/00 ,  C12N2510/02

Abstract: The present invention relates to an improved method for cell line development (CLD) which is generally applicable to production of any therapeutic protein that can be produced using mammalian Cell lines and in particular Chinese Hamster Ovary (CHO) cells.
The method combines site-directed integration (SDI), expression construct components improving the post-transcriptional processing of the gene of interest (GOI) and the introduction of a onetime pre-CLD host cell line selection workflow to generate a production competent cell line that can then be used in multiple CLD efforts using SDI from that point on.

公开(公告)号：US11845973B2

公开(公告)日：2023-12-19

申请号：US17679007

申请日：2022-02-23

Applicant: LG CHEM, LTD.

Inventor： Hye Ok Kang ,  Donggyun Kang ,  Chul Woong Kim ,  In Young Huh ,  Jung Yun Choi

IPC: C08G63/06 ,  C12P7/625 ,  C12N1/20 ,  C12N15/70 ,  C12N9/04 ,  C12N9/02 ,  C12N9/10 ,  C08G63/08 ,  C12N9/88

CPC classification number: C12P7/625 ,  C08G63/06 ,  C08G63/08 ,  C12N1/20 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/1029 ,  C12N9/13 ,  C12N9/88 ,  C12N15/70 ,  C12Y101/01027 ,  C12Y101/01028 ,  C12Y102/01003 ,  C12Y203/01 ,  C12Y208/03001 ,  C12Y402/0103 ,  C12Y402/01036 ,  C12N2510/02

Abstract: The present invention relates to a novel 3-hydroxypropionate-lactate block copolymer [P(3HP-b-LA)], and a method for preparing same, and more specifically, provides a method for preparing a 3-hydroxypropionate-lactate block copolymer, and a 3-hydroxypropionate-lactate block copolymer produced thereby, the method comprising: a first culture step in which, by using recombinant E. coli improved so as to be incapable of biosynthesizing lactic acid, P(3HP) is biosynthesized at the early stage of culturing by having glycerol as a carbon source and through 3-hydroxypropionate-generating genes and an enhanced PHA synthase; and a second culture step in which P(3HP) production is inhibited by using a carbon catabolic repression system for selectively introducing only glucose into E. coli when glycerol and glucose are supplied together as carbon sources, and in which polylactate is biosynthesized to an interrupted P(3HP) terminus by the enabling of the expression of a lactate synthase and a lactyl-CoA converting enzyme through an IPTG induction system.

公开(公告)号：US20230383276A1

公开(公告)日：2023-11-30

申请号：US18188043

申请日：2023-03-22

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Genmin Lu ,  Pamela B. Conley ,  Uma Sinha

IPC: C12N9/64

CPC classification number: C12N9/6432 ,  C12N9/6454 ,  C12N9/64 ,  C12Y304/21006 ,  C12N2510/02

Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.